Longitudinal screening for prostate cancer with prostate-specific antigen

JAMA

Volumn 276, Issue 16, 1996, Pages 1309-1315

  Smith, Deborah S ^a   Catalona, William J ^a   Herschman, Jonathan D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER SCREENING; CANCER STAGING; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0029911467     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.16.1309     Document Type: Article

References (24)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45:8-30.
2. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990;17:719-737.
3. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. CA Cancer J Clin. 1993;43:134-139.
4. Miller BA, Ries LAG, Hankey BF, Kosary CL, Edwards BK, eds. Cancer Statistics Review: 1973-1989. Bethesda, Md: National Cancer Institute; 1992. NIH publication 92-2789.
5. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548-552.
6. Lu-Yao G, Greenberg ER. Changes in prostate cancer incidence and treatment in the USA. Lancet. 1994;343:251-254.
7. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274:1445-1449.
8. Gilliland F, Becker TM, Smith A, Key CR, Samet JM. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol Biomarkers Prev. 1994;3:105-111.
9. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
10. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
11. Lubke WL, Optenberg SA, Thompson IM. Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States. J Natl Cancer Inst. 1994;86:1790-1792.
12. Thompson IM, Optenberg SA. An overview cost-utility analysis of prostate cancer screening. Oncology. 1995;11:141-145.
13. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283-1290.
14. Montie JH. Staging of prostate cancer: current TNM classification and future prospects for prognostic factors. Cancer. 1995;75:1814-1818.
15. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 1994;152:1732-1736.
16. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathologic features of prostatic carcinomas detected via serum prostate specific antigen-based screening. J Urol. 1996;156:816-820.
17. Gleason DF, and the Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, Pa: Lea & Febiger; 1977: 171-197.
18. Colberg JW, Smith DS, Catalona WJ. Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng/ml. J Urol. 1993;149:507-509.
19. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol. 1993;150:106-109.
20. Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol. 1994;152:1737-1740.
21. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147:841-845.
22. Demark-Wahnefried W, Strigo T, Catoe K, et al. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology. 1995;46:346-351.
23. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med. 1995;333:1401-1405.
24. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273:289-294.